-
effectivehealthcare.ahrq.gov/products/childhood-depression/protocol
August 24, 2018 - depression chronicity (first episode vs. recurrent), comorbid conditions, exposure to a traumatic life event … type, severity), history of previous treatment, comorbid condition, and exposure to a traumatic life event … Abbreviations: AE = adverse event; BDI = Beck Depression Inventory; CAS: The Child Assessment Schedule … of the sample (adolescent vs. younger children), comorbid conditions, exposure to a traumatic life event … SH] OR mortality[SH] OR poisoning[SH] OR toxicity[SH] OR adverse effect*[Title/Abstract] OR adverse event
-
effectivehealthcare.ahrq.gov/products/peripheral-artery-disease-effectiveness/abstract
February 08, 2011 - procedure indication) as well as propensity scores used as inverse probability weights in the time to event
-
effectivehealthcare.ahrq.gov/products/adhd/research-protocol
August 10, 2010 - < 6 years of age with ADHD or Disruptive Behavior Disorder, what are the effectiveness and adverse event … Among people 6 years of age or older with ADHD, what are the effectiveness and adverse event outcomes … Descriptive Statistics
Outcomes
Numerical or statistical results of any effectiveness or adverse event … outcomes
Numerical or statistical results of any effectiveness or adverse event outcomes
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain_executive.pdf
October 01, 2011 - or withdrawal due to any adverse event did not
reach statistical significance). … Meloxicam was also
associated with decreased risk of any adverse event
(RR 0.91, 95% CI 0.84 to 0.99) … Etodolac was associated with lower risk of any
adverse event compared to nonselective NSAIDs (RR
0.83 … However, because the event rates increases in older
patients, even if the relative risk estimates are … the
same, the absolute event rates are higher.
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/stroke-atrial-fibrillation_research-protocol.pdf
January 30, 2012 - inhibitors, and considerations for restarting anticoagulation therapy in patients after a
hemorrhagic event … therapy or performing a procedural intervention as a stroke prevention
strategy following a hemorrhagic event … heart failure, coronary artery disease, and high
cholesterol); patients with prior stroke (by type of event … Page 7
o KQ 6: Other strategies for resuming anticoagulation therapy following a hemorrhagic
event … failure, coronary artery disease, and high
cholesterol)
o Patients with prior stroke (by type of event
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/osteoarthritis-pain-2006_appendixes.pdf
January 01, 2006 - 1/00 and
11/30/01;
patients who
changed
medicines were
included in both
groups
Duration to
event … in patients taking low-dose aspirin
and time-to-event of other GI events
including 1) complicated … Cumulative 12-wk incidence of any moderate to severe upper GI AE based on Kaplan-Meier time-to-
event … Lumiracoxib compared less favorably with naproxen (0.37% event rate with lumiracoxib v 0.22%
event rate … COX-2 vs NSAID: Overall RR of any vascular event
among heterogeneous studies 1.0%/yr vs 0.9%/yr
was
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/high-cholestorol-medications_executive.pdf
September 01, 2009 - stroke (hemorrhagic, ischemic, or
unspecified), transient ischemic attack, unspecified
cerebrovascular event … cancer, treatment adherence, withdrawal due to adverse
events, participants with at least one adverse event … Overall, 5 percent of
participants had an event. … Compared with statin monotherapy, more participants
developed at least one adverse event with statin-BAS … Nevertheless, all-cause mortality was a rare event
across most trials.
Followup duration.
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/draft-living-review-plant-chronic-pain-e-cohort-studies.xlsx
March 25, 2024 - C
% (n/N)
Any adverse event
3 months: 35% (19/49) vs. 47% (30/52) vs. NR, RR for A vs. … C
Any adverse event: 26.1% (91/348) vs. 14.9% (56/377); adjusted OR 1.00 (95% CI 0.64 to 1.58) NR No … B
Total patients reporting treatment related adverse event: 21.1% (71/337) vs. 35.0% (118/337), RR 0.60 … B
% (n/N)
Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18)
Serious … error
SF-36 Short-form 36 Question Survey
THC tetrahydrocannabinol
TRAE treatment related adverse event
-
effectivehealthcare.ahrq.gov/products/heart-failure-rehospitalization/research
November 30, 2007 - before the index hospitalization and during followup until being censored or experiencing an outcome event
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/atrial-fibrillation-ablation_executive.pdf
July 01, 2009 - There were 84 studies
that reported at least one adverse event associated with
RFA. … 0 percent
to 5 percent (median 1 percent) of patients in the 70
studies that reported this adverse event … Atrioesophageal
fistula was reported in 26 studies: 5 studies reported 1
case each, with event rates … RFA monitoring and use modalities that are more
sensitive to asymptomatic recurrences of AF (e.g., event … All studies should actively
collect adverse event data from study participants.
-
effectivehealthcare.ahrq.gov/sites/default/files/cer-244-safety-vaccines-update-evidence-summary.pdf
May 01, 2021 - and that the findings of the studies did not constitute
evidence of increased risk of the adverse event … and that the findings of the studies did not constitute
evidence of increased risk of the adverse event … and that the findings of the studies did not constitute
evidence of increased risk of the adverse event … when
determining whether studies are warranted, including the severity and frequency of the
adverse event
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/draft-report-plant-based-treatment.pdf
March 01, 2021 - Understanding how cannabis products’ adverse event profiles compare with other available
treatments … Based on two RCTs, incidence of any adverse
event was significantly higher in the THC/CBD groups than … Although more
patients reported any adverse event while using CBDV than placebo (91% vs. 79%), the … Other key adverse event outcomes (psychosis, cannabis use disorder, cognitive deficits) and
outcomes … Understanding how cannabis products’ adverse
event profiles compare with other available treatments
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2.xlsx
January 22, 2022 - C
% (n/N)
Any adverse event
3 months: 35% (19/49) vs. 47% (30/52) vs. … B
% (n/N)
Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18)
Serious
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Table-E5.xlsx
November 04, 2021 - C
% (n/N)
Any adverse event
3 months: 35% (19/49) vs. 47% (30/52) vs. … B
% (n/N)
Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18)
Serious
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2_0.xlsx
February 16, 2022 - C
% (n/N)
Any adverse event
3 months: 35% (19/49) vs. 47% (30/52) vs. … B
% (n/N)
Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18)
Serious
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/cannabis-app-f5-table-surveillance-report-2_0_0.xlsx
February 16, 2022 - C
% (n/N)
Any adverse event
3 months: 35% (19/49) vs. 47% (30/52) vs. … B
% (n/N)
Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18)
Serious
-
effectivehealthcare.ahrq.gov/sites/default/files/related_files/Appendix-E-Table-E5_0.xlsx
November 04, 2021 - C
% (n/N)
Any adverse event
3 months: 35% (19/49) vs. 47% (30/52) vs. … B
% (n/N)
Any adverse event: 88.4% (190/215) vs. 85.2% (184/216), RR 1.02 (95% CI 0.88 to 1.18)
Serious
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/advanced-care-decision-aids_technical-brief.pdf
July 01, 2014 - Naming of proxy
decisionmaker
Preferences for
emergency
management of
acute life threatening
event … Preferences for ongoing
management of chronic
illness in event of loss of
decisional capacity, … Role definition
for proxy, criteria
to consider
proxy
appropriateness
Probability of
adverse event … proximity to need
for clinical decision
Healthy
End of life
Life threatening
Illness or event … Potentially life
threatening
illness
Hospice or frail
elderly
Life threatening
Illness or event
-
effectivehealthcare.ahrq.gov/products/arthritis-knee-physical-therapy/research-protocol
March 02, 2011 - report the results from random effects models only. 45
The number needed to treat to achieve one event … rate – treatment group event rate). … of avoided or excess events (respectively) per population of 1000 is the difference between the two event … rates multiplied by 1000:
(control group event rate – treatment group event rate)*1000. … Visual Analogue Scale
WOMAC
Western Ontario McMaster
Summary of Protocol Amendments
In the event
-
effectivehealthcare.ahrq.gov/sites/default/files/pdf/adhd_research-protocol.pdf
August 10, 2010 - < 6 years of age with ADHD or Disruptive Behavior
Disorder, what are the effectiveness and adverse event … Among people 6 years of age or older with ADHD, what are the
effectiveness and adverse event outcomes … Descriptive Statistics
Outcomes Numerical or statistical
results of any
effectiveness or adverse
event … outcomes
Numerical or statistical
results of any
effectiveness or adverse
event outcomes